The risk of deep venous thrombosis with oral contraceptives containing drospirenone

Editorial

Nick Dunn. BMJ. 2011.

. 2011 Apr 21:342:d2519.

doi: 10.1136/bmj.d2519.

No abstract available

Comment on

Hormonal contraception and risk of venous thromboembolism: national follow-up study.
Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Lidegaard Ø, et al. BMJ. 2009 Aug 13;339:b2890. doi: 10.1136/bmj.b2890. BMJ. 2009. PMID: 19679613 Free PMC article.
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. van Hylckama Vlieg A, et al. BMJ. 2009 Aug 13;339:b2921. doi: 10.1136/bmj.b2921. BMJ. 2009. PMID: 19679614 Free PMC article.
Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
Parkin L, Sharples K, Hernandez RK, Jick SS. Parkin L, et al. BMJ. 2011 Apr 21;342:d2139. doi: 10.1136/bmj.d2139. BMJ. 2011. PMID: 21511804 Free PMC article.
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
Jick SS, Hernandez RK. Jick SS, et al. BMJ. 2011 Apr 21;342:d2151. doi: 10.1136/bmj.d2151. BMJ. 2011. PMID: 21511805 Free PMC article.